{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(17)"],"submitter":["Wei YF"],"pubmed_abstract":["<b>Introduction</b>: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced <i>EGFR</i>-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. <b>Methods</b>: We conducted a multicenter, prospective study to evaluate improvements in QOL and symptoms in NSCLC patients treated with first-line EGFR-TKIs. QOL was assessed using the instrument of Functional Assessment of Cancer Therapy-Lung questionnaire (FACT-L) and Treatment Outcome Index (TOI). Assessment of symptoms was evaluated using the Lung cancer subscale (LCS). <b>Results</b>: Eligible subjects included 280 patients for endpoint analyses. The mean FACT-L score increased by 4.0 ± 15.56 at Week 2 (p<0.00"],"journal":["Journal of Cancer"],"pagination":["4151-4158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6692623"],"repository":["biostudies-literature"],"pubmed_title":["Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study."],"pmcid":["PMC6692623"],"pubmed_authors":["Huang WT","Chang CC","Lin CM","Wu MF","Ko JC","Wei YF","Shieh JM","Liu TC","Lin CH","Hsia TC","Chian CF"],"additional_accession":[]},"is_claimable":false,"name":"Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.","description":"<b>Introduction</b>: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced <i>EGFR</i>-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. <b>Methods</b>: We conducted a multicenter, prospective study to evaluate improvements in QOL and symptoms in NSCLC patients treated with first-line EGFR-TKIs. QOL was assessed using the instrument of Functional Assessment of Cancer Therapy-Lung questionnaire (FACT-L) and Treatment Outcome Index (TOI). Assessment of symptoms was evaluated using the Lung cancer subscale (LCS). <b>Results</b>: Eligible subjects included 280 patients for endpoint analyses. The mean FACT-L score increased by 4.0 ± 15.56 at Week 2 (p<0.00","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2025-04-21T17:19:15.417Z","creation":"2019-08-21T07:02:42Z"},"accession":"S-EPMC6692623","cross_references":{"pubmed":["31417660"],"doi":["10.7150/jca.30507"]}}